Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 2.89M | $4.0M | 89.69% | +2.87M | 2026-06-30 |
| Lynx1 Capital Management LP | 673.8K | $3.0M | 20.94% | +50.1K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 114.0K | -- | 3.54% | -- | 2026-06-30 |
| Balyasny Asset Management L.P. | 107.0K | -- | 3.33% | -- | 2026-06-30 |
| Ikarian Capital, LLC | 99.5K | -- | 3.09% | +31.4K | 2026-06-30 |
| Yiheng Capital Management, L.P. | 86.1K | -- | 2.68% | -- | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES LLC | 47.9K | -- | 1.49% | -85.7K | 2026-06-30 |
| Erste Asset Management GmbH | 40.7K | -- | 1.26% | -44.6K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 37.0K | -- | 1.15% | -4.4K | 2026-06-30 |
| Verdad Advisers, LP | 30.7K | -- | 0.95% | +8.6K | 2026-06-30 |
